Agenus (NASDAQ:AGEN - Get Free Report) was upgraded by stock analysts at HC Wainwright from a "neutral" rating to a "buy" rating in a report released on Wednesday, MarketBeat.com reports. The brokerage currently has a $25.00 target price on the biotechnology company's stock. HC Wainwright's target price suggests a potential upside of 384.50% from the company's current price.
Other equities research analysts have also recently issued reports about the company. Robert W. Baird lifted their target price on Agenus from $3.00 to $4.00 and gave the stock a "neutral" rating in a report on Tuesday, May 13th. B. Riley reiterated a "buy" rating on shares of Agenus in a research report on Monday, April 21st. Finally, Wall Street Zen raised shares of Agenus from a "strong sell" rating to a "hold" rating in a report on Thursday, May 22nd. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $14.00.
Read Our Latest Stock Analysis on AGEN
Agenus Stock Performance
Shares of NASDAQ AGEN traded down $0.47 during midday trading on Wednesday, hitting $5.16. 1,342,078 shares of the stock traded hands, compared to its average volume of 646,324. The firm has a market capitalization of $141.47 million, a P/E ratio of -0.46 and a beta of 1.48. Agenus has a one year low of $1.38 and a one year high of $18.74. The firm has a 50-day moving average of $2.81 and a two-hundred day moving average of $2.92.
Agenus (NASDAQ:AGEN - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating analysts' consensus estimates of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analysts' expectations of $26.38 million. Equities analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Apollon Wealth Management LLC purchased a new position in Agenus in the fourth quarter worth $55,000. Virtu Financial LLC acquired a new position in shares of Agenus during the fourth quarter valued at about $51,000. Bank of Montreal Can purchased a new position in shares of Agenus in the 4th quarter valued at approximately $69,000. Barclays PLC raised its position in shares of Agenus by 17.7% in the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company's stock valued at $90,000 after purchasing an additional 4,924 shares during the last quarter. Finally, Gilead Sciences Inc. acquired a new stake in Agenus in the 4th quarter worth approximately $635,000. Hedge funds and other institutional investors own 61.46% of the company's stock.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Read More
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
